Data Supporting SeptiCyte® RAPID Performance for COVID-19 Patient Triage Presented at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) by Immunexpress Collaborator

Immunexpress.com

Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced data presented by Immunexpress collaborator from a study supporting SeptiCyte® RAPID performance for COVID-19 patient triage at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) hybrid event, taking place online and in Lisbon, Portugal from April 23-26, 2022. SeptiCyte®…

Read More

Immunexpress CEO To Present at the Virtual Biotech Showcase 2022

Immunexpress.com

Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today that Chief Executive Officer, Rolland Carlson, Ph.D., to present a corporate update, accessible on-demand, at the virtual Biotech Showcase 2022 to be held Jan. 10-12 and Jan. 17–19, 2022.   Dr. Carlson will present an overview of Immunexpress’ SeptiCyte®…

Read More

FDA Clears SeptiCyte® RAPID – The First One-Hour, Direct-from-Blood Sepsis Test

Immunexpress.com

Fully automated diagnostic tool SeptiCyte® RAPID quantifies the relative expression levels of genes involved in a patient’s immune response to infection to aid in a diagnosis in one hour for patients suspected of sepsis Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced that SeptiCyte® RAPID has received…

Read More

Superior Sepsis Diagnostic Performance of SeptiCyte® RAPID Compared to Lactate and Procalcitonin Presented at IDWeek 2021

Immunexpress.com

SeptiCyte® RAPID proved superior to routinely used diagnostic tools for the differentiation of sepsis from infection negative systemic inflammation SEATTLE, Sept. 29, 2021 /PRNewswire/ — Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced a presentation, titled “Comparison of lactate, procalcitonin and a gene signature assay alone or in combination to…

Read More